TargetMol

Naltalimide

Product Code:
 
TAR-T28129
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28129-5mg5mg£1,332.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28129-50mg50mg£2,625.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28129-100mg100mg£3,524.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Naltalimide is a unique ?-opioid receptor partial agonist. Naltalimide also enhances the bladder storage function by modulating the afferent limb of the micturition reflex through ?-opioid receptors in the spinal cord.
CAS:
160359-68-2
Formula:
C28H28N2O5
Molecular Weight:
472.541
Purity:
0.98
SMILES:
[H][C@@]12Oc3c4c(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]5(O)CC[C@H]2N1C(=O)c2ccccc2C1=O)ccc3O

References

1. Fujimura M, Izumimoto N, Momen S, Yoshikawa S, Kobayashi R, Kanie S, Hirakata M, Komagata T, Okanishi S, Hashimoto T, Yoshimura N, Kawai K. Characteristics of TRK-130 (Naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder. J Pharmacol Exp Ther. 2014 Sep;350(3):543-51. doi: 10.1124/jpet.114.214031. Epub 2014 Jun 13. PubMed PMID: 24928951. 2. Atala A. Re: Characteristics of TRK-130 (naltalimide), a novel opioid ligand, as a new therapeutic agent for overactive bladder. J Urol. 2015 Mar;193(3):1060. doi: 10.1016/j.juro.2014.12.029. Epub 2014 Dec 18. PubMed PMID: 25765428. 3. Wein AJ. Re: Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder. J Urol. 2016 Jan;195(1):223. doi: 10.1016/j.juro.2015.10.078. Epub 2015 Nov 21. PubMed PMID: 26699998. 4. Fujimura M, Izumimoto N, Kanie S, Kobayashi R, Yoshikawa S, Momen S, Hirakata M, Komagata T, Okanishi S, Iwata M, Hashimoto T, Doi T, Yoshimura N, Kawai K. Mechanisms of inhibitory action of TRK-130 (Naltalimide), a ?-opioid receptor partial agonist, on the micturition reflex. Int Urol Nephrol. 2017 Apr;49(4):587-595. doi: 10.1007/s11255-017-1509-y. Epub 2017 Jan 16. PubMed PMID: 28093646.